PMC:7283670 / 63163-64113 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T366","span":{"begin":67,"end":69},"obj":"Disease"},{"id":"T367","span":{"begin":128,"end":136},"obj":"Disease"}],"attributes":[{"id":"A366","pred":"mondo_id","subj":"T366","obj":"http://purl.obolibrary.org/obo/MONDO_0005773"},{"id":"A367","pred":"mondo_id","subj":"T367","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Study to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with moderate coronavirus disease (COVID‐19) compared to standard of care treatment Drug: remdesivir, standard of care United States, Hong Kong, 600, all, 18 years and older Treatment Experimental: remdesivir, 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.\nExperimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.\nActive comparator: continued standard of care therapy III Primary (up to 14 days): proportion of participants discharged by day 14‐secondary (up to 10 days): proportion of participants with treatment emergent adverse events leading to study drug discontinuation NCT04292730/Recruiting, Mar‐May 2020"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T583","span":{"begin":43,"end":51},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T584","span":{"begin":251,"end":253},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T585","span":{"begin":444,"end":448},"obj":"http://purl.obolibrary.org/obo/CLO_0001302"},{"id":"T586","span":{"begin":620,"end":624},"obj":"http://purl.obolibrary.org/obo/CLO_0001302"},{"id":"T587","span":{"begin":649,"end":655},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"}],"text":"Study to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with moderate coronavirus disease (COVID‐19) compared to standard of care treatment Drug: remdesivir, standard of care United States, Hong Kong, 600, all, 18 years and older Treatment Experimental: remdesivir, 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.\nExperimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.\nActive comparator: continued standard of care therapy III Primary (up to 14 days): proportion of participants discharged by day 14‐secondary (up to 10 days): proportion of participants with treatment emergent adverse events leading to study drug discontinuation NCT04292730/Recruiting, Mar‐May 2020"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T162","span":{"begin":33,"end":42},"obj":"Chemical"},{"id":"T163","span":{"begin":55,"end":65},"obj":"Chemical"},{"id":"T164","span":{"begin":67,"end":69},"obj":"Chemical"},{"id":"T165","span":{"begin":184,"end":194},"obj":"Chemical"},{"id":"T166","span":{"begin":296,"end":306},"obj":"Chemical"},{"id":"T167","span":{"begin":471,"end":481},"obj":"Chemical"},{"id":"T168","span":{"begin":892,"end":896},"obj":"Chemical"}],"attributes":[{"id":"A162","pred":"chebi_id","subj":"T162","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A163","pred":"chebi_id","subj":"T163","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"},{"id":"A164","pred":"chebi_id","subj":"T164","obj":"http://purl.obolibrary.org/obo/CHEBI_73516"},{"id":"A165","pred":"chebi_id","subj":"T165","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"},{"id":"A166","pred":"chebi_id","subj":"T166","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"},{"id":"A167","pred":"chebi_id","subj":"T167","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"},{"id":"A168","pred":"chebi_id","subj":"T168","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"Study to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with moderate coronavirus disease (COVID‐19) compared to standard of care treatment Drug: remdesivir, standard of care United States, Hong Kong, 600, all, 18 years and older Treatment Experimental: remdesivir, 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.\nExperimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.\nActive comparator: continued standard of care therapy III Primary (up to 14 days): proportion of participants discharged by day 14‐secondary (up to 10 days): proportion of participants with treatment emergent adverse events leading to study drug discontinuation NCT04292730/Recruiting, Mar‐May 2020"}

{"project":"LitCovid-sentences","denotations":[{"id":"T640","span":{"begin":0,"end":456},"obj":"Sentence"},{"id":"T641","span":{"begin":457,"end":648},"obj":"Sentence"},{"id":"T642","span":{"begin":649,"end":950},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Study to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with moderate coronavirus disease (COVID‐19) compared to standard of care treatment Drug: remdesivir, standard of care United States, Hong Kong, 600, all, 18 years and older Treatment Experimental: remdesivir, 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.\nExperimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.\nActive comparator: continued standard of care therapy III Primary (up to 14 days): proportion of participants discharged by day 14‐secondary (up to 10 days): proportion of participants with treatment emergent adverse events leading to study drug discontinuation NCT04292730/Recruiting, Mar‐May 2020"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1893","span":{"begin":80,"end":92},"obj":"Species"},{"id":"1894","span":{"begin":315,"end":327},"obj":"Species"},{"id":"1895","span":{"begin":491,"end":503},"obj":"Species"},{"id":"1896","span":{"begin":748,"end":760},"obj":"Species"},{"id":"1897","span":{"begin":823,"end":835},"obj":"Species"},{"id":"2064","span":{"begin":55,"end":65},"obj":"Chemical"},{"id":"2065","span":{"begin":184,"end":194},"obj":"Chemical"},{"id":"2066","span":{"begin":296,"end":306},"obj":"Chemical"},{"id":"2067","span":{"begin":471,"end":481},"obj":"Chemical"},{"id":"2129","span":{"begin":107,"end":126},"obj":"Disease"},{"id":"2130","span":{"begin":128,"end":136},"obj":"Disease"}],"attributes":[{"id":"A1893","pred":"tao:has_database_id","subj":"1893","obj":"Tax:9606"},{"id":"A1894","pred":"tao:has_database_id","subj":"1894","obj":"Tax:9606"},{"id":"A1895","pred":"tao:has_database_id","subj":"1895","obj":"Tax:9606"},{"id":"A1896","pred":"tao:has_database_id","subj":"1896","obj":"Tax:9606"},{"id":"A1897","pred":"tao:has_database_id","subj":"1897","obj":"Tax:9606"},{"id":"A2064","pred":"tao:has_database_id","subj":"2064","obj":"MESH:C000606551"},{"id":"A2065","pred":"tao:has_database_id","subj":"2065","obj":"MESH:C000606551"},{"id":"A2066","pred":"tao:has_database_id","subj":"2066","obj":"MESH:C000606551"},{"id":"A2067","pred":"tao:has_database_id","subj":"2067","obj":"MESH:C000606551"},{"id":"A2129","pred":"tao:has_database_id","subj":"2129","obj":"MESH:D018352"},{"id":"A2130","pred":"tao:has_database_id","subj":"2130","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Study to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with moderate coronavirus disease (COVID‐19) compared to standard of care treatment Drug: remdesivir, standard of care United States, Hong Kong, 600, all, 18 years and older Treatment Experimental: remdesivir, 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.\nExperimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.\nActive comparator: continued standard of care therapy III Primary (up to 14 days): proportion of participants discharged by day 14‐secondary (up to 10 days): proportion of participants with treatment emergent adverse events leading to study drug discontinuation NCT04292730/Recruiting, Mar‐May 2020"}